European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.

AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of its treatment for acute hepatitis C. The final ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of MAVIRET® ...

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...

EMA committee recommends approval for AbbVie’s Maviret for the treatment of acute hepatitis C infection: North Chicago, Illinois Monday, May 25, 2026, 18:00 Hrs [IST] AbbVie, an ...

Results of a phase IIIb study found the direct-acting antiviral combination of glecaprevir/pibrentasvir to be highly effective and well tolerated in adults with acute ...

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first treatment for acute hepatitis C virus ...

The search for new treatments for hepatitis B has been ongoing for decades. While effective at suppressing the virus, current treatments, which include antivirals, cannot eliminate it from the liver.

Whether hepatitis resolves depends on the type and whether a person receives treatment. Hepatitis A usually resolves without medications, and while sometimes hepatitis B and C may last only a few ...

In phase III study, patients taking bulevirtide had ALT normalization and steep drops in H ...